Outlook Wealth Advisors LLC Takes $477,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Outlook Wealth Advisors LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,136 shares of the medical device company’s stock, valued at approximately $477,000.

Other large investors have also added to or reduced their stakes in the company. Thoroughbred Financial Services LLC acquired a new position in DexCom in the second quarter worth about $211,000. Envestnet Asset Management Inc. raised its position in shares of DexCom by 0.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 599,303 shares of the medical device company’s stock valued at $67,949,000 after acquiring an additional 3,356 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in DexCom by 41.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company’s stock valued at $104,282,000 after purchasing an additional 268,802 shares during the period. Finally, Perennial Investment Advisors LLC grew its position in DexCom by 7.4% in the 2nd quarter. Perennial Investment Advisors LLC now owns 3,156 shares of the medical device company’s stock worth $358,000 after purchasing an additional 217 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of DXCM stock opened at $80.40 on Thursday. The company has a market capitalization of $31.40 billion, a price-to-earnings ratio of 48.14, a P/E/G ratio of 2.00 and a beta of 1.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock’s fifty day simple moving average is $77.57 and its 200-day simple moving average is $78.37.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DXCM. Sanford C. Bernstein lifted their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Raymond James cut their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Royal Bank of Canada lowered their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Citigroup increased their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.